Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates
prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to …

Simple Summary The impact of parathyroid hormone-related protein (PTHrP) and
parathyroid hormone receptor 1 (PTH1R or PTHR1) on cancer initiation, growth, and …

One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting
androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and …

Background Concurrent chemo-radiotherapy (CCRT) is the preferred non-surgical treatment
for patients with locally advanced esophageal squamous cell carcinoma (ESCC) …

Abstract Background Disseminated tumor cells (DTCs) can enter a dormant state and cause
no symptoms in cancer patients. On the other hand, the dormant DTCs can reactivate and …

Simple Summary Avian pathogenic E. coli (APEC) causes localized and systemic infections
that are collectively known as avian colibacillosis. In the poultry industry, APEC infections …

Resistance to androgen receptor (AR) inhibitors, including enzalutamide (Enz), as well as
bone metastasis, are major challenges for castration-resistant prostate cancer (CRPC) …

Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a
significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is …

Antiandrogen therapies are effectively used to treat advanced prostate cancer, but
eventually cancer adaptation drives unresolved metastatic castrate-resistant prostate cancer …

Endochondral ossification is tightly controlled by a coordinated network of signaling
cascades including parathyroid hormone (PTH). Pleckstrin homology (PH) domain and …